Unicycive Therapeutics, Inc. (UNCY)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Net incomeloss attributable to participating securities | - | - | -5,925 | |
| Dividend to series b-1 preferred stockholders | - | - | 887 | |
| Research and development | 1,750 | 3,045 | 4,868 | |
| General and administrative | 5,213 | 3,206 | 2,533 | |
| Total operating expenses | 6,963 | 6,251 | 7,401 | |
| Loss from operations | -6,963 | -6,251 | -7,401 | |
| Interest income | 155 | 416 | 462 | |
| Interest expense | 13 | 15 | 16 | |
| Change in fair value of warrant liability | -374 | -1,754 | -16,810 | |
| Total other income (expenses) | 516 | 2,155 | 17,256 | |
| Net income (loss) | -6,447 | -4,096 | 9,855 | |
| Net income attributable to participating securities | - | - | - | |
| Net income (loss) attributable to common stockholders | -6,447 | -4,096 | 3,043 | |
| Net income (loss) per share attributable to common stockholders, basic (in dollars per share) | -0.52 | -0.05 | 0.08 | |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.52 | -0.05 | -0.15 | |
| Weighted-average shares outstanding used in computing net income (loss) per share, basic (in shares) | 12,302,059 | 88,943,212 | 37,914,812 | |
| Weighted-average shares outstanding used in computing net loss per share, diluted (in shares) | 12,302,059 | 88,943,212 | 94,052,853 | |